


Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300.

Respectfully submitted,



Robert B. Murray
Registration No. 22,980

Customer No. 004372
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810
RBM/epb

86. A composition consisting essentially of, based on the total weight of the composition, β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

87. The composition of claim 86 consisting essentially of, based on the total weight of the composition, β -boswellic acid of at least 14% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 55% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

88. The composition of claim 86 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

89. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 12 to 30% by weight, acetyl- β -boswellic acid of 10 to 25% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

90. The composition of claim 89 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 30% by weight, acetyl- β -boswellic acid of 10 to 20% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

91. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 35% by weight, acetyl- β -boswellic acid of 10 to 20%

by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

92. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 35% by weight, acetyl- β -boswellic acid of 10 to 20% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

93. The composition of claim 86, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

94. A composition comprising three boswellic acids selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is at least 5% by weight, the amount of acetyl- β -boswellic acid is at least 5% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

95. The composition of claim 94, wherein the amount of β -boswellic acid is 14 to 65% by weight, the amount of acetyl- β -boswellic acid is 5 to 65% by weight, the amount of 11-keto- β -boswellic acid is 15 to 60% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 60% by weight.

96. The composition of claim 95, wherein the amount of β -boswellic acid is 14 to 55% by weight, the amount of acetyl- β -boswellic acid is 10 to 55% by weight, the amount of 11-keto- β -boswellic acid is 15 to 50% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 50% by weight.

97. The composition of claim 96, wherein the amount of β -boswellic acid is 14 to 35% by weight, the amount of acetyl- β -boswellic acid is 10 to 35% by weight, the amount of 11-keto- β -boswellic acid is 15 to 40% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 40% by weight.

98. The composition of claim 94, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

99. A composition comprising two boswellic acids selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is 1 to 34% or at least 56% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or at least 46% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

100. The composition of claim 99, wherein the amount of β -boswellic acid is 1 to 34% or 56 to 95% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 46 to 95% by weight, the amount of 11-keto- β -boswellic acid is 15 to 95% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 95% by weight.

101. The composition of claim 100, wherein the amount of β -boswellic acid is 1 to 34% or 56 to 70% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 46 to 70% by weight, the amount of 11-keto- β -boswellic acid is 30 to 70% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 30 to 70% by weight.

102. The composition of claim 101, wherein the amount of β -boswellic acid is 1 to 34% or 40 to 60% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 40 to 60% by weight, the amount of 11-keto- β -boswellic acid is 40 to 60% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 40 to 60% by weight.

103. The composition of claim 99, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

104. A composition comprising boswellic acids, wherein the boswellic acids consist of three substances selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is at least 5% by weight, the amount of acetyl- β -boswellic acid is at least 5% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

105. The composition of claim 104, wherein the amount of β -boswellic acid is 5 to 65% by weight, the amount of acetyl- β -boswellic acid is 5 to 65% by weight, the amount of 11-keto- β -boswellic acid is 15 to 65% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 65% by weight.

106. The composition of claim 105, wherein the amount of β -boswellic acid is 15 to 55% by weight, the amount of acetyl- β -boswellic acid is 15 to 55% by weight, the amount of 11-keto- β -boswellic acid is 15 to 55% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 15 to 55% by weight.

107. The composition of claim 106, wherein the amount of β -boswellic acid is 20 to 40% by weight, the amount of acetyl- β -boswellic acid is 20 to 40% by weight, the amount of 11-keto- β -boswellic acid is 20 to 40% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 20 to 40% by weight.

108. The composition of claim 104, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

114. The composition of claim 94, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

5 115. The composition of claim 94, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

116. The composition of claim 96, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

10 117. The composition of claim 97, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

M 118. The composition of claim 99, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

15 119. The composition of claim 100, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

20 120. The composition of claim 101, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

121. The composition of claim 102, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

25 122. The composition of claim 104, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

30 123. The composition of claim 105, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

124. The composition of claim 106, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

125. The composition of claim 107, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

126. The composition of claim 109, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

127. The composition of claim 110, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

128. The composition of claim 111, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

129. The composition of claim 112, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

130. A method for inhibition of DNA, RNA and/or protein synthesis in a human or animal in need of the inhibition, comprising a step of administering a DNA, RNA and/or protein synthesis inhibition effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

131. The method of claim 130, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

132. The method of claim 131, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

5 133. A method for irreversible inhibition of DNA synthesis in a human or animal in need of the inhibition, comprising a step of administering a DNA inhibition effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

10 134. The method of claim 133, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

15 135. The method of claim 134, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

20 136. A method for the prevention of a lymphoproliferative disease in a human or animal in need of the prevention, comprising a step of administering a lymphoproliferative disease prevention effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

25 137. The method of claim 136, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

138. The method of claim 137, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

5 139. The method of claim 136, wherein the lymphoproliferative disease is leukemia or lymphoma.

10 140. A method for the treatment of a lymphoproliferative disease in a human or animal in need of the treatment, comprising a step of administering a lymphoproliferative disease treatment effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

15 141. The method of claim 140, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

20 142. The method of claim 141, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

143. The method of claim 140, wherein the lymphoproliferative disease is leukemia or lymphoma.

25 144. A method for the prevention of an autoimmune disease in a human or animal in need of the prevention, comprising a step of administering an autoimmune disease prevention effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by

26/10

weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

145. The method of claim 144, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

146. The method of claim 145, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

147. The method of claim 144, wherein the autoimmune disease is psoriasis, sarcoidosis, systemic lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, silent thyroiditis, Crohn's disease, Goodpasture syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, myasthenia gravis, Addison's disease, idiopathic hypoparathyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, rheumatoid arthritis or scleroderma.

148. A method for the treatment of an autoimmune disease in a human or animal in need of the treatment, comprising a step of administering an autoimmune disease treatment effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

149. The method of claim 148, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

150. The method of claim 149, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

151. The method of claim 148, wherein the autoimmune disease is psoriasis, sarcoidosis, systemic lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, silent thyroiditis, Crohn's disease, Goodpasture syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, myasthenia gravis, Addison's disease, idiopathic hypoparathyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, rheumatoid arthritis or scleroderma.

152. A process of obtaining boswellic acids comprising the following steps:

(a) providing a *Boswellia serrata* component;

(b) extracting said *Boswellia serrata* component with carbon dioxide to obtain a fluid extract; and

(c) removing carbon dioxide from the fluid extract to obtain the boswellic acids.

153. The process of claim 152, wherein the *Boswellia serrata* component is a gum from *Boswellia serrata*.

154. The process of claim 152, wherein the extracting in step (b) is performed with subcritical extraction.

155. The process of claim 152, wherein the extracting in step (b) is performed with supercritical extraction.

156. A method for the treatment of a tumor in a human or animal in need of the treatment by administering a tumor treating effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -

26/12

boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

5 157. The method of claim 156, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

10 158. The method of claim 157, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

A 159. A method of inhibiting the synthesis of DNA, RNA and/or protein in a human or animal in need of the inhibition, comprising administering a DNA, RNA and/or protein synthesis inhibition effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

20 160. A method for irreversibly inhibiting the synthesis of DNA in a human or animal in need of the inhibition, comprising administering a DNA synthesis inhibition effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

25 161. A method for preventing or treating a lymphoproliferative disease in a human or animal in need of the prevention or treatment, comprising administering a lymphoproliferative disease preventing or treating effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

26/13

AI 162. A method for preventing or treating an autoimmune disease in a human or animal in need of the prevention or treatment, comprising administering an autoimmune disease preventing or treating effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight
5 or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

163. A composition comprising 11-keto- β -boswellic acid in an amount of at least 5% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 5% by weight.
164. A composition comprising 11-keto- β -boswellic acid in an amount of at least 30% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 30% by weight.
165. A composition comprising 11-keto- β -boswellic acid in an amount of 100% by weight which is the equivalent of 11-keto- β -boswellic acid in an amount of at least 95% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 5% by weight.
166. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising 11-keto- β -boswellic acid.
167. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising acetyl-11-keto- β -boswellic acid.
168. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising β -boswellic acid.
169. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising acetyl- β -boswellic acid.
170. A method for inhibition of DNA, RNA and/or protein synthesis in a human or animal in need of the inhibition, comprising administering a DNA, RNA and/or protein synthesis inhibition effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.
171. A method for irreversible inhibition of DNA synthesis in a human or animal in need of the inhibition, comprising administering a DNA inhibition effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

172: ~~A method for the prevention of a lymphoproliferative disease in a human or animal in need of the prevention, comprising administering a lymphoproliferative disease prevention effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.~~

5

173. A method for the treatment of a lymphoproliferative disease in a human or animal in need of the treatment, comprising administering a lymphoproliferative disease treatment effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

10

174. A method for the prevention of an autoimmune disease in a human or animal in need of the prevention, comprising administering an autoimmune disease prevention effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

15

175. A method for the treatment of an autoimmune disease in a human or animal in need of the treatment, comprising administering an autoimmune disease treatment effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

20

176. A method for the treatment of a tumor in a human or animal in need of the treatment, comprising administering a tumor treating effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.